The anti-fibrotic effects of mTOR inhibition have been reported in various rat models of diabetic nephropathy, glomerulosclerosis, tubulointerstitial fibrosis, and liver cirrhosis [13–16]. This evidence concerns the gene MTOR and diabetic kidney disease.